Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 2/20 | 0.42 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.37 |
| ▸ | MEN1 | O00255 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.37 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.37 |
| ▸ | OXTR | P30559 | 1/20 | 0.37 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.36 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.35 |
| ▸ | ITGAV | P06756 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7018373 | 1.00 | NNMT (0.42) | NNMTMKNK1MKNK2CHRNA7KMT2A | |
| SCHEMBL7140674 | 0.87 | MEN1 (0.41) | NNMTKMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL7554548 | 0.87 | MEN1 (0.41) | NNMTKMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL5091415 | 0.86 | NNMT (0.46) | NNMTMKNK1MKNK2CHRNA7KMT2A | |
| SCHEMBL7081677 | 0.86 | NNMT (0.46) | NNMTMKNK1MKNK2CHRNA7KMT2A | |
| SCHEMBL15913789 | 0.86 | ITGAV (0.36) | CHRNA7KDM4EALDH1A1NR3C1ITGAV | |
| SCHEMBL15913788 | 0.86 | ITGAV (0.36) | CHRNA7KDM4EALDH1A1NR3C1ITGAV | |
| SCHEMBL6106081 | 0.83 | NNMT (0.43) | NNMTMKNK1MKNK2CHRNA7KMT2A | |
| SCHEMBL20153392 | 0.83 | NNMT (0.43) | NNMTMKNK1MKNK2CHRNA7KMT2A | |
| SCHEMBL3727872 | 0.82 | NNMT (0.47) | NNMTMKNK1MKNK2CHRNA7KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140349968-A1 | Compositions and Methods for Treating Cancer | ARIAD PHARMACEUTICALS, INC. (US) | 2014-11-27 | — | — | US | disclosed |
| US-20120289481-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | MERCK SHARP & DOHME CORP. | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289481-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | MTOR, ITGB3, ITGB4 | NNMT 2288/4885MKNK1 118/4885MKNK2 203/4885 |
| US-20140349968-A1 | Compositions and Methods for Treating Cancer | ITGB3, MTOR, ITGA2 | NNMT 1902/4885MKNK1 110/4885MKNK2 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.